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 SUMMARY 
 
Gastroesophageal junction (GEJ) adenocarcinoma are uncommon 
before age of 40 years. While certain clinical, pathological, and 
molecular features of GEJ adenocarcinoma in older patients have been 
extensively studied, these characteristics in the younger population 
remain to be determined. In the recent literature, a high sensitivity and 
specificity for the detection of dysplasia and esophageal 
adenocarcinoma was demonstrated by using multicolor fluorescence 
in situ hybridization (FISH) DNA probe set specific for the locus 
specific regions 9p21 (p16), 20q13.2 and Y chromosome. 
We evaluated 663 patients with GEJ adenocarcinoma and further 
divided them into 2 age-groups of ≤ 40 and ≥ 50 years, respectively. 
FISH with selected DNA probe for Y chromosome, locus 9p21 (p16), 
and locus 20q13.2 was investigated with formalin fixed and paraffin 
embedded tissue from surgical resections of 17 younger and 11 older 
patients. Signals were counted in > 100 cells with each given 
histopathological category. The chromosomal aberrations were then 
compared in the 2 age-groups with the focus on uninvolved squamous 
and columnar epithelium, intestinal metaplasia (Barrett’s mucosa), 
glandular dysplasia, and adenocarcinoma. Comparisons were 
performed by the χ2 test, Fisher's exact test, Student's t-test and Mann-
  2Whitney U-test as appropriate. Survival was estimated by the Kaplan-
Meier method with univariate analysis by the log-rank. Significance 
was taken at the 5% level. 
There was no difference in the surgical technique applied in both age 
groups and most patients underwent Ivor Lewis esophagectomy. 
Among clinical variables there was a higher incidence of smoking 
history in older patient group. We identified a progressive loss of Y 
chromosome from benign squamous epithelium to Barrett’s mucosa 
and glandular dysplasia, and, ultimately, to a near complete loss in 
adenocarcinoma in both age groups. The young group revealed 
significantly more losses of 9p21 in both benign and neoplastic cells 
when compared to the older patients group. In addition, we 
demonstrated an increase in the percentage of cells showing gain of 
locus 20q13.2 with progression from benign epithelium through 
dysplasia to adenocarcinoma with almost the same trend in both the 
young and the older patients. 
When compared with the older age-group, younger patients with GEJ 
adenocarcinoma possess similar known demographics, environmental 
factors, clinical, and pathologic characteristics. The most commonly 
detected genetic aberrations of progressive Y chromosomal loss, 9p21 
locus loss, and 20q13 gains were similar in the younger and older 
patients. However the rate of loss of 9p21 is significantly higher in 
  3young patients, in both the benign and the neoplastic cells. The loss of 
9p21, and possibly, the subsequent inactivation of p16 gene may be 
one of the molecular mechanisms responsible for the accelerated 
neoplastic process in young patients. 
 
  4INTRODUCTION 
 
A rapid increase in the incidence of adenocarcinoma of the distal 
esophagus and gastroesophageal junction (GEJ) has been observed in 
Western countries in the last fifteen years. This has reanimated the 
debate on possible etiologic factors, early diagnosis, and treatment for 
these tumors (1-4). A number of hypotheses have been proposed with 
regard to risk factors for the development of GEJ adenocarcinomas 
that broadly can be divided as environmental and genetic influences 
(5, 6). It is well recognized that patients with longstanding reflux 
esophagitis and subsequent intestinal metaplasia (Barrett’s esophagus) 
are at risk for the development of adenocarcinoma that arises within 
the context of progressive molecular alterations extending through low 
and high grade dysplastic stages (7-9). However, the incidence of 
adenocarcinoma in Barrett’s esophagus is <5% per year (10) thus 
clearly Barrett’s mucosa cannot be the only criterion to recognize 
patients who are at risk for acquiring esophageal adenocarcinoma. 
Therefore, prognostic parameters which can reliably predict malignant 
progression in Barrett’s esophagus are required. It is well documented 
that GEJ adenocarcinoma is most commonly diagnosed in white male 
patients in their sixth and seventh decades of life. The median age for 
patients with adenocarcinoma treated by esophagectomy is 60 to 63 
  5years, and it is extremely rare in patients under 40 years of age (11, 
12). It has been reported that the survival of young patients with these 
tumors is poorer than that of their older patient counterparts (13) 
although the relationship between the clinicopathologic characteristics 
and age of patients with esophageal adenocarcinoma is not clear. In 
addition to our knowledge of known predisposing environmental 
factors, genetic risk factors may also play a significant role in the 
development of GEJ adenocarcinoma. Characterization of the 
underlying molecular mechanisms that promote cancer progression 
could potentially lead to identification of predictive genetic markers 
that classify patient’s malignant risk. Many studies have identified 
common genetic alterations associated with a well defined 
pathological progression from intestinal metaplasia (IM) to low grade 
dysplasia (LGD), to high grade dysplasia (HGD), and then to 
carcinoma. Clinical, pathological, and molecular features of GEJ 
adenocarcinoma in older patients have been extensively studied, but 
the distribution of these characteristics in the younger population 
remains unknown. Genes or genetic loci that have been found to be 
frequently altered include 3p21, 5p15, 5q21-22, EGFR, q36.1, C-myc, 
p16, p53, Her-2/neu, 20q13.2 and the Y chromosome (14-23). In the 
recent literature, a high sensitivity and specificity for the detection of 
dysplasia and esophageal adenocarcinoma was demonstrated by using 
  6multicolor fluorescence in situ hybridization (FISH) DNA probe set 
specific for the locus specific regions 9p21 (p16), 20q13.2 and Y 
chromosome. (24).  
  7AIM OF THE STUDY 
 
In an attempt to better understand the causative pathways and to 
update information on the genetic risk factors related to GEJ 
adenocarcinoma, we evaluated the clinical features and the role of Y 
chromosome, the locus 9p21 (p16) loss, and the ploidy of locus 
20q13.2 in a spectrum of GEJ mucosa including benign squamous and 
columnar epithelium, glandular dysplasia, and the invasive carcinoma 
of patients who underwent surgical treatment under the age of 40 
years, and compared their profile with those of more commonly 
encountered age group (fifth – sixth decades).  
  8METHODS 
 
Patients 
We evaluated 663 patients admitted to surgical treatment for GEJ 
adenocarcinoma and further divided them into 2 age-groups of ≤ 40 
and ≥ 50 years, respectively. We identified 29 patients who developed 
adenocarcinoma under the age of 40 years (mean age of 34.8 ranged 
from 21–39 years). We retrospectively analyzed and compared the 
patient’s demographics, tobacco exposure and presence of 
gastroesophageal reflux disease (GERD) between the two age-groups. 
In addition, we also examined the esophagectomy technique, the 
neoadjuvant chemoradiation therapy status and post resection 
pathologic findings. The pathologic stage was assessed with the 2002 
American Joint Commission on Cancer staging system.(25) 
The disease specific survival was calculated from the date of 
operation. Patients were followed for the survival through November 
30 2006, which constituted the censoring date. The study was 
performed in accordance with the guidelines of the Institutional 
Review Board in existence at the time of this analysis. 
  9Operative procedure 
Selection of operation was based on identification of the tumor 
location and depth of tumor invasion and the status of regional lymph 
node involvement. An Ivor Lewis procedure consisted of a laparotomy 
and a right thoracotomy with an anastomosis in the chest. A 
thoracoabdominal procedure consisted of a single left 
thoracoabdominal incision with an anastomosis in the left chest. A 
McKeown procedure consisted of a laparotomy, a right thoracotomy, 
and a left cervical incision, with an anastomosis in the neck. A 
transhiatal procedure included a laparotomy and a left cervical 
incision, with an anastomosis in the neck. A transabdominal procedure 
consisted of a laparotomy only, with an anastomosis above the hiatus 
and up to the level of the inferior pulmonary vein. 
 
  10Material 
Formalin fixed and paraffin embedded tissue sections from surgically 
resected specimens were examined by gastrointestinal pathologists to 
select pertinent sections to include the spectrum of histopathological 
variant of GEJ mucosa for the subsequent investigation by FISH. 
 
  11Fluorescence in situ hybridization (FISH) 
FISH was performed on serial 4-µm tissue sections. The following 
commercially available fluorescence-labeled, locus-specific (LSI) and 
centromere DNA probes (CEP) (Vysis Inc, Downers Grove, IL, USA) 
were applied according to the manufacturer's instructions: LSI 9p21 
SpectrumOrange/CEP9 SpectrumGreen, LSI 20q13.2 
SpectrumOrange and CEP Y (α satellite) SpectrumOrange. 
More than or less than twice the number of red signals than green 
centromeres signals were scored as a DNA sequence copy number 
gain or loss for LSI probe, respectively. More than or less than twice 
the number of green signals were scored as a DNA sequence copy 
number gain or loss for CEP Y (α satellite) probe, respectively. Digital 
images were acquired with a Zeiss Axioplan2 imaging microscope 
(Carl Zeiss Jena GmbH, Jena, Germany) equipped with a 
PlanApochromat 100×/NA 1.4 oil objective lens and appropriate filter 
settings for DAPI, SpectrumGreen (FITC), and SpectrumOrange 
illumination and detection. 
FISH with selected DNA probes were investigated and compared 
within the groups focusing on uninvolved squamous and columnar 
epithelium, intestinal metaplasia, glandular dysplasia, and 
adenocarcinoma. A minimum of one hundred cells were enumerated 
per hybridization. Nuclei from normal squamous epithelium or 
  12lymphocytes present on the same slide were used as controls of 
hybridization efficiency and specificity. 
 
  13Statistical analysis 
Statistical analysis was performed using the SPSS statistical package, 
version 13.0 (Chicago IL) by the χ
2 test and Fisher's exact test for 
comparison of proportions, and the Mann-Whitney
  U-test for 
comparison of non-parametric data. Comparison of means was based 
on the Student's t-test. Survival was estimated
 by the Kaplan-Meier 
method with univariate analysis by the log-rank. Significance was 
taken
 at the 5%
 level.  
  14RESULTS 
 
Clinical and Pathological Features 
From the 663 patients admitted to surgery for EGJ adenocarcinoma at 
our institution there were 539 males and 124 females. The patient’s 
clinical and pathologic characteristics are summarized in Table 1. 
There was no significant difference in male to female ratio and 
presence of symptoms of GERD within the two age groups. The 
smoking history was more frequently reported in the older patients 
(72% vs. 48%) p=0.001. Most patients underwent Ivor Lewis 
esophagectomy without a significant difference regarding the age. 
Approximately half of the patients in both groups received 
neoadjuvant chemo or chemo-radio therapy due to their locally 
advance disease. The two age populations presented with similar 
pathological characteristics regarding presence of Barrett’s 
epithelium, glandular dysplasia, and histological differentiation of 
their tumors.  Localized disease (pTNM stage 0, I, and IIA) was 
present in 62% young patients and 53% older patients (p=0.79), 
respectively. Survival rate was also similar in the two groups with a 
three years disease specific survival 54% in patients ≤ 40 years and a 
52% in the older ones (p=0.93), respectively.  
  15Table 1 
 
Clinical and pathological characteristics 
 
Patients  N  Mean 
age  M:F  Tobacco  GERD 
history 
(Path) 
Barrett's 
P Stage 
0, I & 
IIa 
Neo 
Adjuvant 
3-Yr 
DFS 
3-Yr 
OS 
≤ 40 y.o.  29  34.5  23: 6  48.3%  31%  41.4%  62.1%  65.5%  54.1%  64% 
≥ 50 y.o.  634  65.7  516: 118  72.1%  35%  45.7%  52.7%  48.7%  52.2%  54% 
p value  <.001  0.78  <.001  0.66  0.83 0.79 0.06  0.93  0.52 
 
 
  16Chromosomal Aberrations by FISH Analysis 
A total of 28 FISH experiments on 17 patients who were ≤ 40 years 
and on 11 patients who were ≥ 50 years were performed using LSI 
9p21 (p16) SpectrumOrange/CEP9 SpectrumGreen and LSI 20q13.2 
SpectrumOrange probes. FISH experiment using CEP Y (α satellite) 
SpectrumOrange was performed on male patients only (12 patients ≤ 
40 years and on 7 patients ≥ 50 years. The control group of 11 patients 
was randomly selected according to reliably match all the clinical and 
pathological characteristics of the entire group of patients ≥ 50 years 
that underwent surgery for EGJ adenocarcinoma. 
 
Y Chromosome Loss 
Y chromosomal loss has been previously established as a common 
chromosomal aberration in GEJ adenocarcinoma. In our comparative 
study between the young and the older patient group, it was apparent 
that there was a progressive loss of Y chromosome from benign 
squamous epithelium to Barrett’s mucosa and dysplasia and a near 
complete loss in adenocarcinoma (90% loss in young and 92% loss in 
older group) (Table 2 and figure 1A, 1B). While there was a slight 
trend of more losses during this pathologic progression in older 
patients, they were not statistically significant different from the 
young group (Figure 2).
  17Table 2 
Average percentage of Y chromosome loss in the different 
histological categories in the two age groups.  
Average percentage of Y chromosome loss (mean±sd) 
Patients N 
Normal Squamous 
Barrett’s  
(if present) 
Dysplasia Adenocarcinoma 
≤ 40 y.o.  12  13.9±7.6  35.2±12.4  70±18.3  90.1±2.19 
≥ 50 y.o.  7  9±2.72  48.7±15.4  86.6±10.1  92.2±5.74 
p value    0.273  0.249  0.179  0.360 
 
  18Figure 1A 
Representative examples of squamous cells with biallelic nuclei for Y 
chromosome (red signal) detected by FISH on formalin fixed and 
paraffin embedded tissue section. 
 
 
 
 
 
 
 
 
 
 
 
  19Figure 1B 
Representative examples of dysplastic cells with monoallelic nuclei 
for Y chromosome (red signal) detected by FISH on formalin fixed 
and paraffin embedded tissue section. 
 
 
 
 
 
 
 
 
 
 
 
 
  20Figure 2 
Average percentage of cells in GEJ mucosa with normal ploidy or loss 
for Y chromosome in the different histological categories in the two 
age groups. 
 
 
 
  219p21 (p16) Loss 
Loss of 9p21 and mutation of the CDKN2/p16 gene have been 
reported to occur in early lesions during neoplastic progression in 
Barrett's esophagus. In this study, we demonstrated a significant 
increase in the percentage of cells showing loss of locus 9p21 during 
the progression from benign squamous epithelium through dysplasia 
to adenocarcinoma in both groups (Table 3 and figure 3). The young 
group revealed significantly more losses of 9p21 in both benign and 
neoplastic cells when compared to the older group, whereas the 
percentage of loss was not significantly different in Barrett’s and in 
the dysplastic epithelium between the two age group (figure 4). The 
significance in loss 9p21 was not altered regardless the presence of 
absence of Barrett’s status in each group (Table 4 and figure 5). 
In addition, when the young patient group was further stratified into 
those with the condition of Barrett’s and those without, the average 
percent of 9p21 loss was significantly higher in benign epithelium 
(19.7 ± 8.1 vs. 12 ± 2.5, p=0.0158) in the former; and the losses of 
9p21 in dysplastic epithelium (51.2 ± 7.2 vs. 53.4 ± 9.4, p=0.6163) 
and in adenocarcinoma (84.7 ± 14.4 vs. 79.6 ± 3.8, p=0.3208) were 
similar regardless the Barrett’s status (Table 5 and figure 6). 
  22Table 3 
Average percentage of locus 9p21 (p16) loss in the different 
histological categories in the two age groups. 
 
Average percentage of 9p21 loss (mean±sd) 
Patients N 
Normal 
Squamous 
Normal 
Columnar 
Barrett’s 
(if 
present) 
Dysplasia Adenocarcinoma 
≤ 40 
y.o.  17  13.9 ± 5.1  25 ± 6.9  45 ± 6.4  48.5 ± 7.9  81 ± 7.6 
≥ 50 
y.o.  11  6.6 ± 4.3  14.6 ± 5.8  55.3 ± 11  46 ± 18.2  39.2 ± 10.5 
p value    0.0006  0.0003  0.0042  0.6201  < 0.0001 
 
  23Figure 3 
Representative examples of tumor cells with aneuploidy nuclei for 
locus 20q13.2 (red signal) detected by FISH on formalin fixed and 
paraffin embedded tissue section. 
 
 
  24Figure 4 
Average percentage of cells in GEJ mucosa with normal ploidy or loss 
for locus 9p21 (p16) within the different histological categories in the 
two age groups. (*= p<0.05) 
 
 
  25Table 4 
Average percentage of locus 9p21 (p16) losses within the different 
histologic categories in the two age groups in patients with Barrett’s 
metaplasia only. 
 
Average percentage of 9p21 losses (mean±sd) 
Patients N 
Normal 
Squamous 
Normal 
Columnar 
Barrett’s 
Esophagus  Dysplasia Adenocarcinoma 
Young  8  19.7 ± 8.1  27.9 ± 11.1  45 ± 6.4  51.2 ± 7.2  84.7± 14.4 
Old  11  6.6 ± 4.3  14.6 ± 5.8  55.3 ± 11  46 ± 18.2  39.2 ± 10.5 
p value    0.0003  0.0033  0.0042  0.4570  < 0.0001 
 
  26Figure 5 
Average percentage of cells in the surgical specimens with normal 
ploidy or loss for locus 9p21 (p16) within the different histologic 
categories in the two age groups in patients with in patients with 
Barrett’s metaplasia only. (*= p<0.05) 
 
 
  27Table 5 
Average percentage of locus 9p21 (p16) losses within the different 
histologic categories in patients ≤ 40years with and without Barrett’s 
metaplasia only. 
 
Average percentage of 9p21 losses (mean±sd) 
Patients N 
Normal 
Squamous 
Normal 
Columnar 
Barrett’s 
Esophagus  Dysplasia Adenocarcinoma 
No 
Barrett  9  12± 2.5  24.1 ± 7.3  -  53.3 ± 9.4  79.6 ± 3.8 
Barrett  8  19.7 ± 8.1  27.9 ± 11.1  45 ± 6.4  51.2 ± 7.2  84.7± 14.4 
p value    0.0158  0.4121  -  0.6163 0.3208 
 
  28Figure 6 
Average percentage of cells in the surgical specimens with normal 
ploidy or loss for locus 9p21 (p16) within the different histologic 
categories in patients ≤ 40years with and without Barrett’s metaplasia 
only. (*= p<0.05) 
 
 
  2920q13.2 Gain 
In contrast to the loss of Y chromosome and 9p21, the gains of locus 
20q13.2 was less significant with progression from benign epithelium 
through dysplasia to adenocarcinoma (Table 6 and figure 7). A 
significant difference between the two age group was only detected in 
the Barrett’s epithelium (young 14.4 ± 4.1 vs. older 11.1 ± 1, p= 
0.015) and in a marginal difference in the adenocarcinoma (young 
25.0 ± 3.5 vs. older 27.6 ± 2.7, p= 0.0466). Nevertheless both groups 
presented almost the same trend of progressive gain of 20q13.2 during 
the dysplastic and neoplastic transformation to carcinoma (Figure 8). 
  30Table 6 
Average percentage of locus 20q13.2 gain within the different 
histologic categories in the two age groups. 
Average percentage of 20q13.2 gain (mean±sd) 
Patients N 
Normal 
Squamous 
Normal 
Columnar 
Barrett’s 
(if 
present) 
Dysplasia Adenocarcinoma 
≤ 40 
y.o.  17  0.3 ± 0.4  1 ± 1.2  14.4 ± 4.1  16.6 ± 6.9  25.0 ± 3.5 
≥ 50 
y.o.  11  0  0.5 ± 1  11.1 ± 1  12.2 ± 6.8  27.6 ± 2.7 
p value    -  0.2621  0.0150  0.1095  0.0466 
 
  31Figure 7 
Representative examples of tumor cells with monoallelic nuclei for 
p16 (red signal) retaining two copies of chromosome 9 (green signal) 
detected by FISH on formalin fixed and paraffin embedded tissue 
section. 
 
 
 
  32Figure 8 
Average percentage of cells in GEJ mucosa with gain or loss of locus 
20q13.2 within the different histological categories in the two age 
groups. (*= p<0.05) 
 
 
  33DISCUSSION 
 
The cause of the increase in the incidence of adenocarcinoma of the 
esophagus and gastroesophageal junction in all age groups over the 
past two decades is unclear.  Parallel to the increase in overall 
incidence, an increase in the number of patients <50 years old as well 
as those with early intramucosal cancer has been recorded (11, 26).  In 
young patients, the cancer is often diagnosed in a more advanced 
stage, possibly because of a delay in diagnosis or because of a more 
biologically aggressive (13). 
Our data suggest that, when compared with the older age-group, 
young patients with GEJ adenocarcinoma possess similar known 
demographics, environmental factors, clinical and pathologic 
characteristics.  Patients in both groups are predominantly males with 
a history of tobacco exposure, gastroesophageal reflux disease and 
Barrett’s metaplasia. There was no significant difference in prevalence 
of early stage disease or disease specific survival when matched for 
tumor stage. An equal group of patients in each group received 
neoadjuvant chemoradiation therapy. Thus, our findings do not 
support the results reported suggesting an higher prevalence of late-
stage disease in younger patients at the time of initial diagnosis (11). 
  34FISH and comparative genomic hybridization (CGH) studies have 
found both gains and losses of chromosomes in the dysplastic and 
malignant GEJ tissue (16, 23, 24, 27-29). 
The most consistent numerical chromosomal aberration found in 
karyotyping and in similar studies is the loss of the Y chromosome 
(30, 31). In GEJ adenocarcinoma, Y chromosome loss was found in 
31% to 93% of the tumors (32). In one study, the frequency of Y 
chromosome loss in Barrett’s esophagus increased along with the 
grade of dysplasia (33). Although Barrett’s associated 
adenocarcinoma occurs more commonly in men, no specific oncogene 
or tumor suppressor genes have been assigned to the Y chromosome. 
It has been proposed that as genetic instability increases during the 
malignant transformation of Barrett’s mucosa, Y chromosome loss 
occurs in a random fashion rather than through a specific pathogenic 
mechanism (32). Evaluation of Y chromosome status by FISH in the 
sequence normal mucosa – metaplasia – dysplasia – adenocarcinoma 
has been previously reported by authors (24, 27). Our results confirm 
the progressive Y chromosome loss in a similar rate in both the young 
and the older patient populations. Thus the loss of Y chromosome is 
associated with the development of GEJ adenocarcinoma of male 
patients in general, but is not restricted to the older age group in 
particular. 
  35Frequent allelic loss of locus 9p12 and the deletion of corresponding 
p16 tumor suppressor gene have been reported to occur early in GEJ 
adenocarcinoma pathway (15, 19), and increase progressively in the 
metaplasia-dysplasia-carcinoma sequence. The p16 gene encodes a 
16-kD protein that forms complexes with the cyclin-dependent kinases 
CDK4 and CDK6, and subsequently inhibits their ability to 
phosphorylate the retinoblastoma protein. Unphosphorylated 
retinoblastoma protein prevents the cell from entering the S phase of 
the cell cycle.  Thus, inactivation of p16 gene may lead to 
uncontrolled cell growth.  Barrett et al. reported a higher prevalence 
(23%) of p16 gene mutations in GEJ adenocarcinoma with loss of 
heterozygosity of 9p21 (20). It has been proposed that inactivation of 
p16 may occur via a number of different molecular mechanisms and 
p16 inactivation could be a useful biomarker to stratify the risk of 
progression of Barrett’s metaplasia to dysplasia and neoplasia (34). 
In our investigation, the young group reveals significantly more losses 
of 9p21 in both benign and neoplastic cells when compared to the 
older group. In addition, the loss was significantly higher in patients 
with Barrett’s esophagus than those without the condition within the 
young age group. A significant loss of 9p21 in benign squamous and 
columnar epithelial cells has not been previously reported. The finding 
of locus 9p21 genomic loss in majority of dysplasia/adenocarcinoma 
  36cases in this study was consistent with the previous observation that 
the deletion of p16 gene locus constitutes a major alteration 
accompanying the progression from Barrett’s esophagus related 
dysplasia to adenocarcinoma (20, 28, 35). However, the observation 
of a >80% loss of 9p21 in carcinoma cells in young patients has 
exceeded the previously reported loss in adenocarcinoma of GEJ in 
general patient populations (35% - 70%) (24, 27, 36). It is thus 
plausible that the loss of 9p21 and the subsequent inactivation of p16 
in benign appearing and pre-metaplastic epithelial cells constitutes one 
of the molecular mechanisms that are responsible for the accelerated 
and early development on adenocarcinoma in young patients. 
Chromosome arm 20q was a frequent target of DNA copy gain, 
usually consisting of gain of the entire chromosome, with a few 
tumors showing gain of the long arm alone (37). 
In particular, 20q13 has been shown to be a frequent site of 
amplification in breast cancer and amplification of this locus has been 
associated with immortalization of cells in tissue culture (38). Walch 
et al. described amplification of locus 20q13.2 by FISH in a subset of 
patients with esophageal adenocarcinoma (29), and this feature has 
been confirmed by other studies (39, 40). The most frequently 
upregulated genes associate with this gain are ZNF217, BCAS1 and 
CYP24 (41). 
  37Similar to previously reported data, our studies have demonstrated an 
increase in the percentage of cells showing locus 20q13.2 gain with 
progression from benign epithelium through dysplasia to 
adenocarcinoma with almost the same trend in the young and the older 
group. While a marginal statistical difference are detected in the 
percentage of nuclei with abnormalities in Barrett’s epithelium and in 
adenocarcinoma between the two age groups, it is unclear that this 
difference is responsible for the cancerogenetic process in these 
patients. 
  38CONCLUSIONS 
 
Patients with GEJ adenocarcinoma who are ≤ 40 years old share 
similar clinical and molecular findings with those reported in older 
patients. Thus GEJ adenocarcinomas in younger are likely to evolve 
from similar mechanisms of tumor pathogenesis. Possible additional 
molecular alterations responsible for an eventual accelerated 
neoplastic process in young patients may include an early and a 
significant loss and inactivation of p16 gene among other molecular 
and genetic mechanisms. 
Current recommendation regarding indications for endoscopy 
surveillance in patients with symptomatic reflux have focused on 
patients over 50-60 years of age (42). Despite advances in endoscopic 
technology, screening and surveillance strategies for early detection of 
these tumors have had limited efficacy in preventing these deadly 
tumors (43). Advances in technologies and molecular diagnosis offer 
the promise to understand the pathogenesis of this type of 
adenocarcinoma; among those, FISH may offer a more practical and 
accurate surveillance tool for patients with GEJ adenocarcinoma. It is 
clear that young patients with Barrett’s esophagus are not immune to 
the development of adenocarcinoma and that a liberal use of a 
molecularly-tailored diagnostic approach may be an appropriate 
  39measure to increase the rate of disease detected at an early curable 
stage. 
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